Skip to contentM
Mangoceuticals, Inc.
M
MGRXMangoceuticals, Inc. Q3 2025 · 10-Q
Revenue$84.25K$84.25K−36.8% vs Q3 2024 Net Income-$7.62M-$7.62MN/M vs Q3 2024 EPS Diluted-$0.69-$0.69N/M vs Q3 2024 Gross Profit$50,899−38.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Mangoceuticals, Inc. · CIK 1938046 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,241,264N/M Margins · derivedGross margin60.4%−1.6 pt vs Q3 2024
Operating margin-8953.5%−7635.2 pt vs Q3 2024
Net margin-9042.8%−7543.8 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end